Dimethylphenylpiperazinium

Dimethylphenylpiperazinium (DMPP) is a nicotinic acetylcholine receptor agonist which is selective for the ganglionic subtype.[1] One of the earliest reports on the pharmacology of DMPP, describing it as a ganglion-stimulating, hypertensive agent, came from Graham Chen and his co-workers at Parke, Davis & Co. (Now Pfizer)[2]

Dimethylphenylpiperazinium
Identifiers
  • 1,1-Dimethyl-4-phenylpiperazin-1-ium
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H19N2
Molar mass191.298 g·mol−1
3D model (JSmol)
  • C[N+]1(CCN(CC1)C2=CC=CC=C2)C
  • InChI=1S/C12H19N2/c1-14(2)10-8-13(9-11-14)12-6-4-3-5-7-12/h3-7H,8-11H2,1-2H3/q+1 checkY
  • Key:MKGIQRNAGSSHRV-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

See also

References
  1. Prado WA, Segalla DK (August 2004). "Antinociceptive effects of bethanechol or dimethylphenylpiperazinium in models of phasic or incisional pain in rats". Brain Research. 1018 (2): 272–82. doi:10.1016/j.brainres.2004.05.085. PMID 15276888.
  2. Chen G, Portman R, Wickel A (November 1951). "Pharmacology of 1,1-dimethyl-4-phenylpiperazinium iodide, a ganglion stimulating agent". The Journal of Pharmacology and Experimental Therapeutics. 103 (3): 330–6. PMID 14898449.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.